A NEED OF BETTER PHARMACOVIGILANCE SYSTEM IN INDIA
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i1.14797Abstract
India is one of the top producers of generics globally and is currently being recognized as the pharmacy of the world†for the generic drug products. Thus, there is a need that it has best health-care systems in place to regulate and provide better quality drugs by monitoring the possible risk associated with the use of drugs. Being the generic hub, physicians, pharmacists, etc., should be erudite to provide an alternative cost-effective generic medicine, which is one of the education-related aspects of pharmacovigilance. We need a more systematic approach to surveillance of drug-related problems, which is at the heart of pharmacovigilance. The health-care system requires new processes to understand the risk-benefit ratio of drugs. The challenges in implementation of better pharmacovigilance in country due to nonavailability of trained staff in pharmacovigilance, lack of training of health-care professionals on drug safety, and adverse drug reaction reporting which comprises adverse interactions of medicines with chemicals, other medicines, and food are often neglected leading to under-reporting by health-care professionals as well as patients, lack of expertise, etc., should be overcome by Indian regulatory body via practical oriented knowledge-based system. The web market monitoring, global electronic database, education, association of stakeholders and regulation of herbal medicines standards and allied medicinal systems are vital restructurings needed to be introduced for a better pharmacovigilance system in India.
Keywords: Pharmacovigilance, India.
Downloads
References
WHO. Definition of Pharmacovigilance. Geneva: WHO; 2002.
Ahmad A, Patel I, Sanyal S, Balkrishnan R, Mohanta GP. A study on drug safety monitoring program in India. Indian J Pharm Sci
;76(5):379-86.
CDSCO, Ministry of Health and Family Welfare, Government of India.
Pharmacovigilance Programme of India. New Delhi: CDSCO, Ministry of Health and Family Welfare, Government of India; 2010.
Almenoff JS. Innovations for the future of pharmacovigilance. Drug Saf 2007;30(7):631-3.
Arora D. Pharmacovigilance obligations of the pharmaceutical companies in India. Indian J Pharmacol 2008;40 Suppl 1:S13-6.
Brahmachari B. Pharmacovigilance for clinical trials in India: Current practice and areas for reform. Perspect Clin Res 2011;2(2):49-53.
Pandemic Pharmacovigilance Weekly Update Status, 2009. Available from: http://www.ema.europa.eu/pdfs/influenza/78468109en.pdf. [Last cited on 2010 Jan 12].
Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med 2003;348(25):2526-34.
CIOMS Working Group IV. Benefit-risk Balance for Marketed Products: Evaluating Safety Signals. Geneva: Council for International Organizations of Medical Sciences (CIOMS); 1999.
Roy K, Divya S, Nadig P, Prakash B. Monitoring and analysis of adverse drug reactions in a private tertiary care teaching hospital. Asian J Pharm Clin Res 2015;8(2):337.
Eisenhauer LA. Adverse drug reactions: A concern for clinicians and patients. Clin Excell Nurse Pract 2002;6:3-7.
El Emam K, Jonker E, Sampson M, Krleza-Jeric K, Neisa A. The use of electronic data capture tools in clinical trials: Web-survey of 259
Canadian trials. J Med Internet Res 2009;11(1):e8.
European Monitoring Centre for Drugs and Drug Addiction. The Internet and Drug Markets. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2016.
Barratt MJ, Lenton S, Allen M. Internet content regulation, public drug websites and the growth in hidden internet services. Drugs Educ Prev Policy 2013;20(3):195-202.
Edwards B, Olsen AK, Whalen MD, Gold MJ. Guiding principles of safety as a basis for developing a pharmaceutical safety culture. Curr Drug Saf 2007;2(2):135-9.
Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: Where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 2011;34(3):187-97.
Baghel M. The national pharmacovigilance program for Ayurveda, Siddha and Unani drugs: Current status. Int J Ayurveda Res
;1(4):197-8.
Chaudhary A, Singh N, Kumar N. Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations. J Ayurveda Integr Med
;1(4):251-6.
Report of CIOMS (Council for International Organisations of Medical Sciences) Working Group III. Guidelines for Preparing Core Clinical- Safety Information on Drugs. Geneva: Council for International Organisations of Medical Sciences; 1995.
CIOMS Working Group VIII. Practical Aspects of Signal Detection in Pharmacovigilance. Geneva: Council for International Organizations of Medical Sciences (CIOMS); 2010.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical Safety Data: Data Elements for the Transmission of Individual Case Safety Reports E2B (R2). Step 4 Dated 05 February, 2001.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice E6 R1. Step 4 Dated 10 June, 1996. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. [Last accessed on
Jan 06].
US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Safety Assessment for IND Safety Reporting. Guidance for Industry. Draft Guidance December, 2015. Available from: http://www.fda.gov/ucm/ groups/fdagov-public/@fdagov-drugs gen/documents/document/ ucm477584.pdf. [Last accessed on 2016 Jan 06].
Michel DJ, Knodel LC. Program coordinated by a drug information service to improve adverse drug reaction reporting in a hospital. Am J Hosp Pharm 1986;43(9):2202-5.
Abideen PS. Practical implications of spontaneous adverse drug reaction reporting system in hospitals-an overview. Asian J Pharm Clin Res 2013;6(4):11.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
